Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma

  • Authors:
    • Yu‑Sheng Wang
    • Wei‑Bing Shuang
    • Ke‑Qiang Yin
    • Xu‑Nan Tong
    • Man‑Cheng Xia
    • Hao‑Sen Yang
  • View Affiliations

  • Published online on: July 19, 2019     https://doi.org/10.3892/mco.2019.1900
  • Pages: 405-410
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to identify the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma (SRCC). Between January 2000 and September 2017, a total of 21 patients were enrolled, all of whom were diagnosed with SRCC. In total, eight prognostic factors were analyzed using the Kaplan‑Meier estimator, a log‑rank test and Cox's proportional hazards model. The log‑rank test results revealed that there was a significant association between the proportion of sarcoma elements and survival time of patients with SRCC (P<0.05). In addition, there was a significant association between post‑operative drug treatment and SRCC survival time (P<0.05). The results of the Kaplan‑Meier estimate demonstrated that the survival curve of post‑operative drug treatment was significantly greater compared with the survival curve of patients who did not undergo drug treatment (P<0.05). The survival curve of patients with a proportion of sarcoma elements <50% was significantly greater compared with the survival curve of patients with a proportion of sarcoma elements ≥50% (P<0.05). Furthermore, the Cox's proportional hazards model revealed that the mortality risk in post‑operative patients without drug treatment was 5.822 times greater compared with that of patients with drug treatment (P<0.05). Mortality risk in patients with a proportion of sarcoma elements ≥50% was 4.682 times higher compared with that of patients with sarcoma elements <50% (P<0.05). Finally, post‑operative drug therapy was revealed to be a protective factor which significantly affected the survival time of patients with SRCC [risk ratio (RR)=0.172], in addition to the proportion of sarcoma elements ≥50% (RR=4.682). In conclusion, drug therapy should be promoted upon patient diagnosis with SRCC and attention should be given to the proportion of sarcomatoid components.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI

2 

Dingwei YE and Zhang H: Current status and development trend of renal cancer diagnosis and treatment in China. Chine J Urol. 35:401–405. 2014.(In Chinese).

3 

Xian WEI, Xinwen KE, Zhiquan HU, et al: Clinical efficacy and safety of sunitinib in the treatment of advanced renal cell carcinoma. J Mod Reprod Oncol. 9:133–136. 2017.(In Chinese).

4 

Shuang WB, Zhang YH and Tong XN: Recent researches on sarcomatoid renal cell carcinoma. E J Transl Med. 2:6–8. 2018.(In Chinese).

5 

Zhang L, Wu B, Zha Z, Zhao H and Feng Y: The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: A systematic review and meta-analysis. Cancer Manag Res. 10:1687–1703. 2018. View Article : Google Scholar : PubMed/NCBI

6 

Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC and Costello BA: A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 115:405–411. 2015. View Article : Google Scholar : PubMed/NCBI

7 

He H and Magi-Galluzzi C: Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat Pathol. 21:174–180. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, et al: Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer. 13:e79–e85. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ and Drakaki A: Epidemiology, biology and treatment of sarcomatoid RCC: Current state of the art. World J Urol. 37:115–123. 2019. View Article : Google Scholar : PubMed/NCBI

10 

Appleman LJ and Marachie JK: Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions. Urol Oncol. 36:17–22. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Nanus DM, Garino A, Milowsky MI, Larkin M and Dutcher JP: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 101:1545–1551. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Rashid MH, Welsh CT, Bissada NK and Chaudhary UB: Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol. 28:107–108. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA and Tannir NM: Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: Comparison between the cytokine and targeted therapy eras. J Urol. 198:530–537. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW and Belldegrun AS: Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 109:1600–1606. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA and Sexton WJ: Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 13:225–230. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Chen JH, Liu XD and Yang LI: Sarcomatoid renal cell carcinoma: One case report. J Kun Ming Med Univ. 29:483–484. 2007.

17 

Pei XK, Jiang W, Yang SB, Yang QS and Long W: A case of ipsilateral renal sarcomatoid renal cell carcinoma with angiomyolipoma at the same time and literature review. J Contemp Urol Reproduct Oncol. 304–305. 2014.

18 

Yin MX, Zhang Y, Ye XQ, Lin B and Xiao C: Sarcomatoid renal cell carcinoma: Two case reports. Chin J Clin Exp Pathol. 26:767–768. 2010.(In Chinese).

19 

Li L and Zhou GY: Sarcomatoid renal cell carcinoma: Two case reports. Chin J Clin Exp Pathol. 20:3842004.(In Chinese).

20 

Hu YC, Huang XY, Li D, Leng J, Bo JJ and Wang YX: Sarcomatoid renal cell carcinoma: One case report. Chin J Urol. 23:2172002.(In Chinese).

21 

Komeya M, Sano F, Kagota M, Murakami T, Makiyama K, Miyoshi Y, Nakaigawa N, Ogawa T, Uemura H, Yao M, et al: Case of sarcomatoid renal cell carcinoma developed in the chalked kidney (putty kidney). Hinyokika Kiyo. 55:253–257. 2009.(In Japanese). PubMed/NCBI

22 

Ni XH, Yu GH, Ruan ZY, Lin J and Cai FB: Sarcomatoid renal cell carcinoma: Three cases report. Chin J Urol. 21:506–507. 2000.(In Chinese).

23 

Gao Y, Shuang WB, Tong XN, Li S and Zhang YH: Bilateral sarcomatoid renal cell carcinoma: An uncommon case in young femal patient. Transl Surg. 2:74–77. 2017. View Article : Google Scholar

24 

Takada T, Kinouchi T, Kinoshita T, Hatano K, Kobayashi M, Inoue H, Hara T and Yamaguchi S: Four cases of sarcomatoid renal cell carcinoma. Hinyokika Kiy. 55:93–97. 2009.(In Japanese).

25 

Tsuchiyama K, Ito H, Ishida H, Itoh H and Yokoyama O: Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: Report of a case. Hinyokika Kiy. 57:615–618. 2011.

26 

Minagawa T, Nishizawa S, Kamigaito M, Nakayama T and Okaneya T: Sarcomatoid renal cell carcinoma with von Hippel-Lindau disease: A case report. Nihon Hinyokika Gakkai Zasshi. 98:723–726. 2007.(In Japanese). PubMed/NCBI

27 

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC and Ku JH: Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol. 95:317–323. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R and Belldegrun A: Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 17:523–528. 1999. View Article : Google Scholar : PubMed/NCBI

29 

Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM and Vogelzang NJ: Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 170:1141–1145. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Motzer RJ and Russo P: Systemic therapy for renal cell carcinoma. J Urol. 163:408–417. 2000. View Article : Google Scholar : PubMed/NCBI

31 

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 295:2516–2624. 2006. View Article : Google Scholar : PubMed/NCBI

32 

Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG and Bajorin DF: Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol. 18:840–846. 2000. View Article : Google Scholar : PubMed/NCBI

33 

Bono AV and Lovisolo JA: Renal cell carcinoma-diagnosis and treatment: State of the art. Eur Urol. 31 (Suppl 1):S47–S55. 1997. View Article : Google Scholar

34 

Zhang L, Shi HY and Hong BF: The clinicopathological analysis of 16 cases of sarcomatoid renal cell carcinoma. Med J Chin PLA. 356–358. 2006.

35 

Grabowski M, Huzarski T, Lubinski J and Sikorski A: Survival in patients with rare subtypes of renal cell carcinoma. BJU Int. 89:599–600. 2002. View Article : Google Scholar : PubMed/NCBI

36 

Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA and Belldegrun A: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer. 98:2566–2575. 2003. View Article : Google Scholar : PubMed/NCBI

37 

Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B and Bukowski MSM: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 23:45102005. View Article : Google Scholar

38 

Culine S, Bkradda M, Terrier-Lacombe MJ and Droz JP: Treatment of sarcomatoid renal cell carcinoma: Is there a role for chemotherapy? Eur Urol. 27:138–141. 1995. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 11 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, Y., Shuang, W., Yin, K., Tong, X., Xia, M., & Yang, H. (2019). Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma. Molecular and Clinical Oncology, 11, 405-410. https://doi.org/10.3892/mco.2019.1900
MLA
Wang, Y., Shuang, W., Yin, K., Tong, X., Xia, M., Yang, H."Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma". Molecular and Clinical Oncology 11.4 (2019): 405-410.
Chicago
Wang, Y., Shuang, W., Yin, K., Tong, X., Xia, M., Yang, H."Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma". Molecular and Clinical Oncology 11, no. 4 (2019): 405-410. https://doi.org/10.3892/mco.2019.1900